On May 08, 2014, Medgenics Inc (NYSEMKT:MDGN), reported financial results for the three months ended March 31, 2014 and the filing with the U.S. Securities and Exchange Commission (SEC) of the Company’s Quarterly Report on Form 10-Q. Gross and net research and development expense for the three months ended March 31, 2014 increased to $2.15 million from $2.03 million for same period in 2013. This increase was due mainly to increased stock-based compensation expenses related to options granted to research and development personnel. Medgenics Inc (NYSEMKT:MDGN), weekly performance is 3.81%. On last trading day company shares ended up $7.09. Analysts mean target price for the company is $14.00. Medgenics Inc (NYSEMKT:MDGN), distance from 50-day simple moving average (SMA50) is 0.70%.
Ambit Biosciences Corp (NASDAQ:AMBI)‘s stock had its “buy” rating reaffirmed by analysts at Citigroup Inc. in a research report issued to clients and investors on Wednesday, Analyst Ratings Network reports. They currently have a $14.00 price target on the stock, down from their previous price target of $17.00. Citigroup Inc.’s price target points to a potential upside of 135.69% from the stock’s previous close. Ambit Biosciences Corp (NASDAQ:AMBI), fell 0.06% in last trading session and ended the day on $6.42. AMBI, return on assets is -20.50%. Ambit Biosciences Corp (NASDAQ:AMBI), quarterly performance is -39.03%.
Codexis, Inc. (NASDAQ:CDXS), a leading developer of biocatalysts for the pharmaceutical and fine chemical industries, announced its financial results for the first quarter ended March 31, 2014. Revenues for the first quarter of 2014 were $7.1 million, a 38% decrease from $11.5 million in the first quarter of 2013. Biocatalyst product revenue in the first quarter of 2014 was $3.0 million, a 67% decrease from $9.1 million in the prior year quarter. Codexis, Inc. (NASDAQ:CDXS), shares moved down 2.80% in last trading session and was closed at $1.39, while trading in range of $1.35 – 1.48. Codexis, Inc. (NASDAQ:CDXS), year to date (YTD) performance is -0.71%.
ANI Pharmaceuticals Inc (NASDAQ:ANIP), Director Tracy Marshbanks unloaded 1,381 shares of ANI Pharmaceuticals stock on the open market in a transaction dated Thursday, May 8th. The shares were sold at an average price of $30.02, for a total value of $41,457.62. ANI Pharmaceuticals Inc (NASDAQ:ANIP), ended the last trading day at $29.24. Company weekly volatility is calculated as 6.35% and price to cash ratio as 29.71. ANI Pharmaceuticals Inc (NASDAQ:ANIP), showed a negative weekly performance of 3.69%.
On May 14, 2014, Concert Pharmaceuticals Inc (NYSE:JMPC), reported financial results for the first quarter of 2014. Cash, cash equivalents and investments as of March 31, 2014, totaled $108.0 million as compared to $32.7 million as of December 31, 2013. In the first quarter of 2014, Concert announced the closing of its initial public offering, raising net proceeds of $83.1 million including the exercise of the underwriters’ overallotment option on March 3, 2014. Based upon Concert’s current operating budget, the Company expects that its cash, cash equivalents and investments as of March 31, 2014 will be sufficient to fund operations into 2016. Concert Pharmaceuticals Inc (NYSE:JMPC), net profit margin is -71.50% and weekly performance is -17.53%. On last trading day company shares ended up $25.46. Analysts mean target price for the company is $26.50. Concert Pharmaceuticals Inc (NYSE:JMPC), distance from 50-day simple moving average (SMA50) is -30.59%.